RecruitingRecurrent PericarditisHeart DiseasesPericarditis
Transition to KPL-387 Monotherapy Dosing & Administration Study
Eligible age
18–80 yrs
Accepts
All genders
Locations
9 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Sponsor: Kiniksa Pharmaceuticals International, plc
Where it's recruiting
Source: ClinicalTrials.gov · NCT07288216 · last updated 2026-06-22